ASBM Letter to Idaho Board of Pharmacy
August 6, 2014
The Idaho Board of Pharmacy held a hearing on August 5th and 6th regarding proposed regulations for the treatment of biosimilars in their state. View ASBM letter here.
ASBM Letter to Idaho Board of Pharmacy
August 6, 2014
The Idaho Board of Pharmacy held a hearing on August 5th and 6th regarding proposed regulations for the treatment of biosimilars in their state. View ASBM letter here.
Senate HELP Committee authors letter to HHS Secretary on biosimilars issues
August 1, 2014
View letter here.
Senate HELP Committee authors letter to HHS Secretary on biosimilars issues
August 1, 2014
View letter here.
ASBM member RetireSafe conducts senior survey on knowledge and safety issues concerning biosimilars
July 18, 2014
A new RetireSafe survey, published July 15th, finds seniors largely are unaware of “biosimilar” drugs and overwhelmingly support strong patient safeguards for biosimilar development and FDA approval.
In the survey, senior respondents supported robust clinical trials, unique names for biosimilar drugs, as well as physician and patient notification of biosimilar substitution.
To view the RetireSafe survey information and results, click here.
Pennsylvania has a chance to update its law to allow for biosimilar medicine substitutions – Pittsburgh Post Gazette
July 9, 2014
See article here.
Pennsylvania has a chance to update its law to allow for biosimilar medicine substitutions – Pittsburgh Post Gazette
July 9, 2014
See article here.
EU Commission publishes “What you need to know about biosimilar medicinal products”
July 9, 2014
Translations of the European Commission’s Consensus Information Document on biosimilars is now available in French, German, Italian and Spanish.
The documents were created to foster stakeholders’ understanding of biosimilars in Member States and is a result of a cooperation of all relevant European stakeholders. The papers can be found on the European Commission’s website.
Also to learn more information from ASBM member partner EuropaBio, who helped sponsor the translation, please click here.
